Long‐term benefit from adjuvant tamoxifen therapy for ER + HER2− breast cancer by PR positivity

Documenti analoghi

• Progesterone receptor ( PR ) intra‐tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial
  di: Oscar Danielsson, et al.
  Pubblicazione: (2025)
• An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia
  di: Jefferson Antonio Buendía
  Pubblicazione: (2013)
• Functional combination of resveratrol and tamoxifen to overcome tamoxifen‐resistance in breast cancer cells
  di: Aliaa M. Radwan, et al.
  Pubblicazione: (2024)
• Switching to camizestrant prolonged PFS for patients with ER‐positive, HER2‐negative advanced breast cancer
  di: Leah Lawrence
  Pubblicazione: (2025)
• Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer
  di: Jasmine S. Sukumar, et al.
  Pubblicazione: (2024)